A Danish Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation Who Receive Complete Revascularization

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit of ICD-implantation in patients with coronary artery disease (including acute myocardial infarction), who survive cardiac arrest due to ventricular fibrillation/sustained ventricular tachycardia and undergo revascularization and with an LVEF above 35%.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with CAD and cardiac arrest due to VF/VT, where angiogram is performed with complete revascularization (PCI, CABG or hybrid coronary revascularization) before ICD implantation. Unfavorable artery for PCI (i.e., excessive vessel tortuosity or chronic total occlusion) or high-risk invasive treatment is not mandatory in order to achive complete revascularization.

• Age ≥18 years

• LVEF \>35% at the time of discharge. The most recent LVEF assessment on which the current medical treatment will be based at the time of entry into the study will be used as baseline LVEF.

Locations
Other Locations
Denmark
Copenhagen University Hospital, Rigshospitalet
RECRUITING
Copenhagen
Contact Information
Primary
Reza Jabbari, MD, PhD
reza.jabbari.02@regionh.dk
+4535455380
Backup
Thomas Engstrøm, MD, PhD, DMSc
thomas.engstroem@regionh.dk
+4535458444
Time Frame
Start Date: 2020-10-12
Estimated Completion Date: 2032-10
Participants
Target number of participants: 1200
Treatments
Experimental: ICD-implantation
Implantation of an ICD either during admission or within 4 weeks after discharge from index event.
No_intervention: Standard care
Guideline directed medical therapy
Sponsors
Leads: Rigshospitalet, Denmark

This content was sourced from clinicaltrials.gov